CINRYZE Support

Jeanie, a real HAE patient,
helps prevent her
attacks with CINRYZE

Getting Started With OnePath^®

Product support for your HAE journey

OnePath is committed to helping eligible people who have been prescribed CINRYZE to treat hereditary angioedema (HAE) gain access to their medication. When you begin therapy with CINRYZE through OnePath, you are offered a service with helpful Case Managers who are ready to assist you with your product support needs.

If you have not already been signed up for OnePath, please talk to your healthcare provider about getting started.

OnePath provides product support

A Case Manager can work with you to help ensure you have access to the medication you need.
OnePath offers self-administration training at your physician's request. A specially trained infusion nurse will train you on the proper techniques for preparing and administering your CINRYZE infusions if you decide you would like to self-administer your therapy.

Do not try to self-administer CINRYZE until a
healthcare professional has taught you how.

Are you ready to move forward with self-administration?

Learn more about the Path to Independence^™ Program.

See self-administration training

OnePath can help you with insurance access and coverage issues

A Case Manager will perform a full insurance benefit exploration to help ensure that you understand your coverage for CINRYZE.
A local Patient Access Manager can work with you to address any insurance or access-related issues.
OnePath also provides information about financial assistance programs to help eligible patients pay for their medicine.

Contacting OnePath

Call: 1-866-888-0660
Monday through Friday, 8:30 a.m. to 8:00 p.m. ET

You might also be interested in:

Events Resource Library Sign Up for Information

ExpandClose Important Safety Information

You should not use CINRYZE if you have had life-threatening immediate hypersensitivity reactions, including anaphylaxis to the product.

Tell your healthcare provider about all of your medical conditions, including if you: have an indwelling catheter/access device in one of your veins; have a history of blood clots, heart disease, or stroke; or are taking birth control pills or androgens. Also tell your healthcare provider if you are pregnant or planning to become pregnant, or are breastfeeding or planning to breastfeed. It is not known if CINRYZE can harm your unborn baby, or if CINRYZE passes into your milk and if it can harm your baby.

Allergic reactions may occur with CINRYZE. Call your healthcare provider or get emergency support services right away if you have any of the following symptoms: wheezing, difficulty breathing, chest tightness, turning blue (look at lips and gums), fast heartbeat, swelling of the face, faintness, rash, hives.

Serious blood clots may occur with CINRYZE. Call your healthcare provider or get emergency support services right away if you have any of the following symptoms: pain and/or swelling of an arm or leg with warmth over the affected area, discoloration of an arm or leg, unexplained shortness of breath, chest pain or discomfort that worsens on deep breathing, unexplained rapid heart rate, numbness or weakness on one side of the body.

Because CINRYZE is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

The most common side effects seen with CINRYZE were headache, nausea, rash, and vomiting. These are not all the possible side effects of CINRYZE. Tell your healthcare provider about any side effect that bothers you or that does not go away. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see the Full Prescribing Information.

Mix2Vial is a registered trademark of Medimop Medical Projects, Ltd. in the United States and other jurisdictions.

This site is intended for U.S. residents and is governed by U.S. law and governmental regulations. Please see our online Privacy Policy for more information.
S10685 08/2016